Author:
Kalyoncu Umut,Kasifoglu Timuçin,Omma Ahmet,Bes Cemal,Cinar Muhammet,Emmungil Hakan,Kucuksahin Orhan,Akar Servet,Aksu Kenan,Yildiz Fatih,Kanitez Nilüfer Alpay,Erden Abdulsamet,Bilgin Emre,Dalkilic Ediz,Ermurat Selime,Hayran Mutlu
Reference9 articles.
1. Adult-onset Still's disease in focus: clinical manifestations, diagnosis, treatment, and unmet needs in the era of targeted therapies;Efthimiou;Semin Arthritis Rheum,2021
2. Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still's disease;Gabay;Ann Rheum Dis,2018
3. Adult Still's disease: manifestations, disease course, and outcome in 62 patients;Pouchot;Medicine (Baltimore),1991
4. Clinical manifestations but not cytokine profiles differentiate adult-onset Still's disease and sepsis;Rau;J Rheumatol,2010
5. Regression coefficient-based scoring system should be used to assign weights to the risk index;Mehta;J Clin Epidemiol,2016
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献